tiprankstipranks
Advertisement
Advertisement

ALKS Stock Latest News

Alkermes price target raised to $61 from $54 at Needham
The FlyAlkermes price target raised to $61 from $54 at Needham
4d ago
ALKS
Alkermes price target raised to $50 from $42 at TD Cowen
PremiumThe Fly
Alkermes price target raised to $50 from $42 at TD Cowen
6d ago
ALKS
Alkermes Elevated to $50 Price Target as Orexin Leadership and Alixorexton Pipeline Drive Buy Rating
PremiumRatings
Alkermes Elevated to $50 Price Target as Orexin Leadership and Alixorexton Pipeline Drive Buy Rating
7d ago
ALKS
Alkermes data support alixorexton in narcolepsy type 2, says H.C. Wainwright
PremiumThe Fly
Alkermes data support alixorexton in narcolepsy type 2, says H.C. Wainwright
10d ago
ALKS
Alkermes Price Target Reaffirmed at $43 as Encouraging Vibrance-2 Data Support Neutral Stance
PremiumRatings
Alkermes Price Target Reaffirmed at $43 as Encouraging Vibrance-2 Data Support Neutral Stance
10d ago
ALKS
Closing Bell Movers: Rumble rallies on expansion into AI business
PremiumThe FlyClosing Bell Movers: Rumble rallies on expansion into AI business
11d ago
NUE
RUM
Alkermes reports ‘positive results’ from Vibrance-2 Phase 2 study of alixorexton
Premium
The Fly
Alkermes reports ‘positive results’ from Vibrance-2 Phase 2 study of alixorexton
11d ago
ALKS
Alkermes Gains Orphan Status For Sleep Disorder Therapy
Premium
Company Announcements
Alkermes Gains Orphan Status For Sleep Disorder Therapy
13d ago
8K
ALKS
Alkermes announces ODD for Alixorexton in the U.S., Europe
PremiumThe Fly
Alkermes announces ODD for Alixorexton in the U.S., Europe
13d ago
ALKS
Alkermes’ alixorexton granted orphan designation for idiopathic hypersomnia
PremiumThe Fly
Alkermes’ alixorexton granted orphan designation for idiopathic hypersomnia
17d ago
ALKS
Alkermes price target raised to $56 from $45 at RBC Capital
PremiumThe Fly
Alkermes price target raised to $56 from $45 at RBC Capital
19d ago
ALKS
Alkermes to present new data on Alixorexton, LUMRYZ
PremiumThe Fly
Alkermes to present new data on Alixorexton, LUMRYZ
24d ago
ALKS
Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target
PremiumRatingsNeedham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target
1M ago
ALKS
Alkermes Shareholders Approve Amended Stock Incentive Plan
Premium
Company Announcements
Alkermes Shareholders Approve Amended Stock Incentive Plan
1M ago
8K
ALKS
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge
Premium
Company Announcements
Alkermes’ Earnings Call Highlights Growth and LUMRYZ Surge
1M ago
ALKS
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline
PremiumCompany Announcements
Alkermes Advances Phase 3 Narcolepsy Study With ALKS 2680, Adding a New Catalyst to Its Pipeline
1M ago
ALKS
Alkermes price target raised to $48 from $45 at Baird
PremiumThe Fly
Alkermes price target raised to $48 from $45 at Baird
2M ago
ALKS
Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study
PremiumThe Fly
Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study
2M ago
ALKS
Alkermes Reports Positive Phase 3 Results for LUMRYZ
PremiumCompany Announcements
Alkermes Reports Positive Phase 3 Results for LUMRYZ
2M ago
8K
ALKS
Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market
PremiumCompany AnnouncementsAlkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market
2M ago
ALKS
Alkermes price target raised to $48 from $42 at UBS
Premium
The Fly
Alkermes price target raised to $48 from $42 at UBS
2M ago
ALKS
Alkermes price target raised to $50 from $45 at Needham
Premium
The Fly
Alkermes price target raised to $50 from $45 at Needham
2M ago
LLY
ALKS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >